We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02580305
Recruitment Status : Completed
First Posted : October 20, 2015
Last Update Posted : November 23, 2020
Sponsor:
Information provided by (Responsible Party):
Suven Life Sciences Limited

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: SUVN-502 Drug: Placebo Drug: Donepezil Drug: Memantine Phase 2

Detailed Description:

This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving donepezil HCl (10 mg qd) and either memantine HCl (10 mg twice daily [bid]) or Namenda XR® (Extended Release, 28 mg qd) or the combination therapy, Namzaric™

The primary objective of the study is to evaluate the efficacy of a serotonin receptor subtype 6 (5-HT6) antagonist, SUVN-502, compared to placebo, as adjunct treatment in subjects with moderate Alzheimer's disease (Mini-Mental State Examination [MMSE] score of 12 to 20) currently treated with the acetylcholinesterase inhibitor, donepezil hydrochloride (HCl), and the N-methyl-D-aspartic acid (NMDA) antagonist, memantine HCl. Efficacy will be assessed by the 11-item Alzheimer's Disease Assessment Scale for Cognitive Behavior (ADAScog-11) after 26 weeks of treatment.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 564 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Study Start Date : September 2015
Actual Primary Completion Date : November 5, 2019
Actual Study Completion Date : November 7, 2019

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Experimental: SUVN-502 Low dose (50 mg)
SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
 Drug: SUVN-502
Once-daily, tablets, orally
Other Name: Masupirdine

Drug: Donepezil
Donepezil HCl (10 mg, once a day)
Other Name: Namzaric

Drug: Memantine
Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Other Name: Namenda XR®
Active Comparator: Experimental: SUVN-502 High dose (100 mg)
SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
 Drug: SUVN-502
Once-daily, tablets, orally
Other Name: Masupirdine

Drug: Donepezil
Donepezil HCl (10 mg, once a day)
Other Name: Namzaric

Drug: Memantine
Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Other Name: Namenda XR®
Placebo Comparator: Placebo
Placebo adjunct to base treatment with Donepezil and Memantine
 Drug: Placebo
Once-daily, tablets, orally

Drug: Donepezil
Donepezil HCl (10 mg, once a day)
Other Name: Namzaric

Drug: Memantine
Memantine HCl (10 mg, twice a day or 28 mg extended-release, once a day).
Other Name: Namenda XR®


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in cognition [ Time Frame: Screening, Baseline, Week 4, 13 and 26 ]
    Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAScog -11) total score


Secondary Outcome Measures :
  1. Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) [ Time Frame: Baseline, Week 4, 13 and 26 ]
    Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

  2. Change in functioning [ Time Frame: Baseline, Week 4, 13 and 26 ]
    Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) total score

  3. Change in behavioural disturbance [ Time Frame: Baseline, Week 4, 13 and 26 ]
    Neuropsychiatric Inventory (NPI) 12 item

  4. Depression and Dementia [ Time Frame: Screening, Baseline, Week 4, 13. 26 and 30 ]
    Cornell Scale for Depression and Dementia (C-SDD)

  5. Risk of suicidality [ Time Frame: Screening, Baseline, Week 4, 13. 26 and 30 ]
    Columbia Suicide Severity Rating Scale (C-SSRS)

  6. Change in cognitive aspects of mental function [ Time Frame: Screening, Baseline, Week 4, 13 and 26 ]
    Change in Mini Mental State Examination (MMSE)

  7. Safety and tolerability [ Time Frame: Up to 26 weeks and a 4-week safety follow up ]
    Number of patients with adverse events


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a diagnosis of probable Alzheimer's disease based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria at least 1 year prior to the screening visit.
  • Has a score between 12 and 20 inclusive on the MMSE at the screening and baseline visits.
  • Has a MRI or CT scan performed within 12 months prior to screening with findings consistent with the diagnosis of dementia due to Alzheimer's disease without any other clinically significant comorbid pathologies.
  • Must be receiving treatment with stable doses of donepezil HCl and memantine HCl for at least 3 months prior to the screening visit
  • Availability of an eligible and reliable caregiver
  • Must be living in the community or an assisted living facility.
  • Must be ambulatory or ambulatory aided (use of cane or walker).
  • Is not pregnant or planning to become pregnant during the study.
  • Subject (or subject's legally acceptable representative) and caregiver must sign an Informed Consent to participate in the study.

Exclusion Criteria:

  • Has a diagnosis of dementia due to other than Alzheimer's Disease
  • Is taking cholinesterase inhibitors other than donepezil HCl or taking doses of donepezil HCl other than 10 mg
  • Is taking doses of memantine HCl other than 10 mg bid or Namenda XR® 28 mg qd.
  • Has uncontrolled cardiac disease or hypertension.
  • Has clinically significant renal or hepatic impairment.
  • Has cancer or a malignant tumor, untreated thyroid disorder or has a history of seizure disorder
  • Is treated or likely to require treatment during the study, with any medications prohibited by the study protocol.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02580305


Locations
Show Show 71 study locations
Sponsors and Collaborators
Suven Life Sciences Limited
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Suven Life Sciences Limited
ClinicalTrials.gov Identifier: NCT02580305    
Other Study ID Numbers: CTP2S1502HT6
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 2020
Keywords provided by Suven Life Sciences Limited:
SUVN-502
5-HT6
Phase 2
Cognition
Donepezil
 Memantine
Alzheimer's Disease
Triple Combination
Proof of Concept (POC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Memantine
Donepezil
1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1H-indole dimesylate monohydrate
Cholinesterase Inhibitors
 Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Serotonin Antagonists
Serotonin Agents